clopidogrel + aspirin

Clopidogrel + aspirin is a combination antiplatelet therapy investigated for the treatment of acute ischemic stroke. Clopidogrel is a thienopyridine-class small molecule that acts as a selective and irreversible antagonist of the P2Y12 adenosine diphosphate (ADP) receptor on platelets, thereby inhibiting ADP-induced platelet aggregation. Aspirin (acetylsalicylic acid) is a salicylate that irreversibly inhibits cyclooxygenase-1 (COX-1), preventing the synthesis of thromboxane A2, a potent mediator of platelet activation. This specific dual antiplatelet therapy (DAPT) regimen, often involving a 300 mg loading dose of clopidogrel and 100 mg of aspirin, was evaluated by the General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Region) in the EAST trial. The study focused on the early administration of DAPT within 6 hours of intravenous thrombolysis in patients with minor acute ischemic stroke to prevent early neurological deterioration. Results published in 2025 indicated that while the regimen was safe, it did not significantly improve functional outcomes compared to standard care in this specific patient population.

Brand names

Clopitab-ALDeplatt AClopivas APClavix-ASClopilet ACeruvin APreva-ASPlagerine-ACeruvin AFClopikind-AS

Other names

clopidogrel plus aspirindual antiplatelet therapyDAPT